Zum Inhalt

HealthOSArzneimittel

Arbeitsbereiche

Nachschlagen

Wirkstoffe & Arzneimittelsicherheit

Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.

Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.

RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.

Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

HOS-097274 · Fachinformation

Quellenpassagen (19)

Gegenanzeigen · Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

Pregabalin Viatris Pharma 25 mg hard capsules Pregabalin Viatris Pharma 50 mg hard capsules Pregabalin Viatris Pharma 75 mg hard capsules Pregabalin Viatris Pharma 100 mg hard capsules Pregabalin Viatris Pharma 150 mg hard capsules Pregabalin Viatris Pharma 200 mg hard capsules Pregabalin Viatris Pharma 225 mg hard capsules Pregabalin Viatris Pharma 300 mg hard capsules · Abschnitt 4.3 · PDF-Seite 5

HOS-132654 · Präparat HOS-097274

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-09-24T15:36:00Z · SHA-256 82ee888afd9191364ca2885cfe33f3a6014857efdff1de95ea2361849731a42c · Passage 8cc0fe29768569a55e0703c8413d5a145077448bca5f7426ab9084406d167fa6 · Zeichen 0–91 im Abschnitt

Wechselwirkungen · Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

Pregabalin Viatris Pharma 25 mg hard capsules Pregabalin Viatris Pharma 50 mg hard capsules Pregabalin Viatris Pharma 75 mg hard capsules Pregabalin Viatris Pharma 100 mg hard capsules Pregabalin Viatris Pharma 150 mg hard capsules Pregabalin Viatris Pharma 200 mg hard capsules Pregabalin Viatris Pharma 225 mg hard capsules Pregabalin Viatris Pharma 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8

HOS-132655 · Präparat HOS-097274

Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (< 2% of a dose recovered in urine as metabolites), does not inhibit drug metabolism in vitro, and is not bound to plasma proteins, it is unlikely to produce, or be subject to, pharmacokinetic interactions.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-09-24T15:36:00Z · SHA-256 82ee888afd9191364ca2885cfe33f3a6014857efdff1de95ea2361849731a42c · Passage c651509beb7d54b8248f912ed7c51fe80c381560bdfb94755dd9831ab5655e70 · Zeichen 0–315 im Abschnitt

Wechselwirkungen · Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

Pregabalin Viatris Pharma 25 mg hard capsules Pregabalin Viatris Pharma 50 mg hard capsules Pregabalin Viatris Pharma 75 mg hard capsules Pregabalin Viatris Pharma 100 mg hard capsules Pregabalin Viatris Pharma 150 mg hard capsules Pregabalin Viatris Pharma 200 mg hard capsules Pregabalin Viatris Pharma 225 mg hard capsules Pregabalin Viatris Pharma 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8

HOS-132656 · Präparat HOS-097274

In vivo studies and population pharmacokinetic analysis Accordingly, in in vivo studies no clinically relevant pharmacokinetic interactions were observed between pregabalin and phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam, oxycodone or ethanol. Population pharmacokinetic analysis indicated that oral antidiabetics, diuretics, insulin, phenobarbital, tiagabine and topiramate had no clinically significant effect on pregabalin clearance.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) tiagabine (HOS-112899) topiramate (HOS-110310) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) oxycodone (HOS-109487) lorazepam (HOS-085981) gabapentin (HOS-090745) ethanol (HOS-089988) phenytoin (HOS-084531)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-09-24T15:36:00Z · SHA-256 82ee888afd9191364ca2885cfe33f3a6014857efdff1de95ea2361849731a42c · Passage da089224ea0ec4abc0cbed18c715ba22143350e7ab711c5dc56268bbae3381d5 · Zeichen 317–785 im Abschnitt

Wechselwirkungen · Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

Pregabalin Viatris Pharma 25 mg hard capsules Pregabalin Viatris Pharma 50 mg hard capsules Pregabalin Viatris Pharma 75 mg hard capsules Pregabalin Viatris Pharma 100 mg hard capsules Pregabalin Viatris Pharma 150 mg hard capsules Pregabalin Viatris Pharma 200 mg hard capsules Pregabalin Viatris Pharma 225 mg hard capsules Pregabalin Viatris Pharma 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8

HOS-132661 · Präparat HOS-097274

Oral contraceptives, norethisterone and/or ethinyl oestradiol Co-administration of pregabalin with the oral contraceptives norethisterone and/or ethinyl oestradiol does not influence the steady-state pharmacokinetics of either substance.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-09-24T15:36:00Z · SHA-256 82ee888afd9191364ca2885cfe33f3a6014857efdff1de95ea2361849731a42c · Passage 2a3eac6786eafb172300f87d1240cb59f571423679075f32969897b5a1280e8f · Zeichen 787–1024 im Abschnitt

Wechselwirkungen · Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

Pregabalin Viatris Pharma 25 mg hard capsules Pregabalin Viatris Pharma 50 mg hard capsules Pregabalin Viatris Pharma 75 mg hard capsules Pregabalin Viatris Pharma 100 mg hard capsules Pregabalin Viatris Pharma 150 mg hard capsules Pregabalin Viatris Pharma 200 mg hard capsules Pregabalin Viatris Pharma 225 mg hard capsules Pregabalin Viatris Pharma 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8

HOS-132662 · Präparat HOS-097274

Central nervous system influencing medical products Pregabalin may potentiate the effects of ethanol and lorazepam.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lorazepam (HOS-085981) ethanol (HOS-089988)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-09-24T15:36:00Z · SHA-256 82ee888afd9191364ca2885cfe33f3a6014857efdff1de95ea2361849731a42c · Passage 1da4d7084b9ec6fc1aee195f48f0aaa7ece0af34de7f4681c55889b6b54753df · Zeichen 1026–1141 im Abschnitt

Wechselwirkungen · Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

Pregabalin Viatris Pharma 25 mg hard capsules Pregabalin Viatris Pharma 50 mg hard capsules Pregabalin Viatris Pharma 75 mg hard capsules Pregabalin Viatris Pharma 100 mg hard capsules Pregabalin Viatris Pharma 150 mg hard capsules Pregabalin Viatris Pharma 200 mg hard capsules Pregabalin Viatris Pharma 225 mg hard capsules Pregabalin Viatris Pharma 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8

HOS-132663 · Präparat HOS-097274

In the postmarketing experience, there are reports of respiratory failure, coma and deaths in patients taking pregabalin and opioids and/or other central nervous system (CNS) depressant medicinal products. Pregabalin appears to be additive in the impairment of cognitive and gross motor function caused by oxycodone.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): oxycodone (HOS-109487)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-09-24T15:36:00Z · SHA-256 82ee888afd9191364ca2885cfe33f3a6014857efdff1de95ea2361849731a42c · Passage 4a33bdabdd55eaf2dcb1fc5914a87ba24a9543b80086d57d33957e486a06efb8 · Zeichen 1143–1459 im Abschnitt

Wechselwirkungen · Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

Pregabalin Viatris Pharma 25 mg hard capsules Pregabalin Viatris Pharma 50 mg hard capsules Pregabalin Viatris Pharma 75 mg hard capsules Pregabalin Viatris Pharma 100 mg hard capsules Pregabalin Viatris Pharma 150 mg hard capsules Pregabalin Viatris Pharma 200 mg hard capsules Pregabalin Viatris Pharma 225 mg hard capsules Pregabalin Viatris Pharma 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8

HOS-132664 · Präparat HOS-097274

Interactions and the elderly No specific pharmacodynamic interaction studies were conducted in elderly volunteers. Interaction studies have only been performed in adults.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-09-24T15:36:00Z · SHA-256 82ee888afd9191364ca2885cfe33f3a6014857efdff1de95ea2361849731a42c · Passage bd16812c3b5f312846e443af505b6fb6f4de8633019b6ae93c7f1b115538e824 · Zeichen 1461–1631 im Abschnitt

Nebenwirkungen · Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

Pregabalin Viatris Pharma 25 mg hard capsules Pregabalin Viatris Pharma 50 mg hard capsules Pregabalin Viatris Pharma 75 mg hard capsules Pregabalin Viatris Pharma 100 mg hard capsules Pregabalin Viatris Pharma 150 mg hard capsules Pregabalin Viatris Pharma 200 mg hard capsules Pregabalin Viatris Pharma 225 mg hard capsules Pregabalin Viatris Pharma 300 mg hard capsules · Abschnitt 4.8 · PDF-Seite 9

HOS-132665 · Präparat HOS-097274

The pregabalin clinical programme involved over 8,900 patients exposed to pregabalin, of whom over 5,600 were in double-blind placebo controlled trials. The most commonly reported adverse reactions were dizziness and somnolence. Adverse reactions were usually mild to moderate in intensity. In all controlled studies, the discontinuation rate due to adverse reactions was 12% for patients receiving pregabalin and 5% for patients receiving placebo. The most common adverse reactions resulting in discontinuation from pregabalin treatment groups were dizziness and somnolence.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-09-24T15:36:00Z · SHA-256 82ee888afd9191364ca2885cfe33f3a6014857efdff1de95ea2361849731a42c · Passage f0628b730d2ad571569c1887dd33919ae954ffce1d70dbfbf4f2dea5b36a74a9 · Zeichen 0–575 im Abschnitt

Nebenwirkungen · Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

Pregabalin Viatris Pharma 25 mg hard capsules Pregabalin Viatris Pharma 50 mg hard capsules Pregabalin Viatris Pharma 75 mg hard capsules Pregabalin Viatris Pharma 100 mg hard capsules Pregabalin Viatris Pharma 150 mg hard capsules Pregabalin Viatris Pharma 200 mg hard capsules Pregabalin Viatris Pharma 225 mg hard capsules Pregabalin Viatris Pharma 300 mg hard capsules · Abschnitt 4.8 · PDF-Seite 9

HOS-132666 · Präparat HOS-097274

In table 2 below all adverse reactions, which occurred at an incidence greater than placebo and in more than one patient, are listed by class and frequency (very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-09-24T15:36:00Z · SHA-256 82ee888afd9191364ca2885cfe33f3a6014857efdff1de95ea2361849731a42c · Passage 87c88db6fd8a88101bcfe55224916952801a2a42929ae878efd452906c0dbf3b · Zeichen 577–1031 im Abschnitt

Nebenwirkungen · Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

Pregabalin Viatris Pharma 25 mg hard capsules Pregabalin Viatris Pharma 50 mg hard capsules Pregabalin Viatris Pharma 75 mg hard capsules Pregabalin Viatris Pharma 100 mg hard capsules Pregabalin Viatris Pharma 150 mg hard capsules Pregabalin Viatris Pharma 200 mg hard capsules Pregabalin Viatris Pharma 225 mg hard capsules Pregabalin Viatris Pharma 300 mg hard capsules · Abschnitt 4.8 · PDF-Seite 9

HOS-132667 · Präparat HOS-097274

The adverse reactions listed may also be associated with the underlying disease and/or concomitant medicinal products.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-09-24T15:36:00Z · SHA-256 82ee888afd9191364ca2885cfe33f3a6014857efdff1de95ea2361849731a42c · Passage 9b83a8664ff43c5e30df46e4f1e5836b5d50e9fc21b9a6862e2afebed35d6b2f · Zeichen 1033–1151 im Abschnitt

Nebenwirkungen · Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

Pregabalin Viatris Pharma 25 mg hard capsules Pregabalin Viatris Pharma 50 mg hard capsules Pregabalin Viatris Pharma 75 mg hard capsules Pregabalin Viatris Pharma 100 mg hard capsules Pregabalin Viatris Pharma 150 mg hard capsules Pregabalin Viatris Pharma 200 mg hard capsules Pregabalin Viatris Pharma 225 mg hard capsules Pregabalin Viatris Pharma 300 mg hard capsules · Abschnitt 4.8 · PDF-Seite 9

HOS-132668 · Präparat HOS-097274

In the treatment of central neuropathic pain due to spinal cord injury the incidence of adverse reactions in general, CNS adverse reactions and especially somnolence was increased (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-09-24T15:36:00Z · SHA-256 82ee888afd9191364ca2885cfe33f3a6014857efdff1de95ea2361849731a42c · Passage 938f8b79aa2e22ae92da4a69c200df2125860743877b8a24bb69a7fa1ce0a44c · Zeichen 1153–1351 im Abschnitt

Nebenwirkungen · Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

Pregabalin Viatris Pharma 25 mg hard capsules Pregabalin Viatris Pharma 50 mg hard capsules Pregabalin Viatris Pharma 75 mg hard capsules Pregabalin Viatris Pharma 100 mg hard capsules Pregabalin Viatris Pharma 150 mg hard capsules Pregabalin Viatris Pharma 200 mg hard capsules Pregabalin Viatris Pharma 225 mg hard capsules Pregabalin Viatris Pharma 300 mg hard capsules · Abschnitt 4.8 · PDF-Seite 9–10

HOS-132669 · Präparat HOS-097274

9 Additional reactions reported from postmarketing experience are included in italics in the list below.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-09-24T15:36:00Z · SHA-256 82ee888afd9191364ca2885cfe33f3a6014857efdff1de95ea2361849731a42c · Passage c5bdc2f3d1f7fb183e3cadc98f6553f505640cc14f27932154cd1f36d030a10a · Zeichen 1406–1511 im Abschnitt

Nebenwirkungen · Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

Pregabalin Viatris Pharma 25 mg hard capsules Pregabalin Viatris Pharma 50 mg hard capsules Pregabalin Viatris Pharma 75 mg hard capsules Pregabalin Viatris Pharma 100 mg hard capsules Pregabalin Viatris Pharma 150 mg hard capsules Pregabalin Viatris Pharma 200 mg hard capsules Pregabalin Viatris Pharma 225 mg hard capsules Pregabalin Viatris Pharma 300 mg hard capsules · Abschnitt 4.8 · PDF-Seite 10

HOS-132670 · Präparat HOS-097274

Table 2. Pregabalin Adverse Drug Reactions

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-09-24T15:36:00Z · SHA-256 82ee888afd9191364ca2885cfe33f3a6014857efdff1de95ea2361849731a42c · Passage 688d99769d3520b4e31d4281db78eadae2a6d402918303a13bc72192cbc466d5 · Zeichen 1513–1555 im Abschnitt

Nebenwirkungen · Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

Pregabalin Viatris Pharma 25 mg hard capsules Pregabalin Viatris Pharma 50 mg hard capsules Pregabalin Viatris Pharma 75 mg hard capsules Pregabalin Viatris Pharma 100 mg hard capsules Pregabalin Viatris Pharma 150 mg hard capsules Pregabalin Viatris Pharma 200 mg hard capsules Pregabalin Viatris Pharma 225 mg hard capsules Pregabalin Viatris Pharma 300 mg hard capsules · Abschnitt 4.8 · PDF-Seite 10

HOS-132671 · Präparat HOS-097274

System Organ Class Adverse drug reactions Infections and infestations Common Nasopharyngitis Blood and lymphatic system disorders Uncommon Neutropaenia Immune system disorders Uncommon Hypersensitivity Rare Angioedema, allergic reaction Metabolism and nutrition disorders Common Appetite increased Uncommon Anorexia, hypoglycaemia Psychiatric disorders Common Euphoric mood, confusion, irritability, disorientation, insomnia, libido decreased Uncommon Hallucination, panic attack, restlessness, agitation, depression, depressed mood, elevated mood, aggression, mood swings, depersonalisation, word finding difficulty, abnormal dreams, libido increased, anorgasmia, apathy Rare Disinhibition, suicidal behaviour, suicidal ideation Not known Drug dependence Nervous system disorders Very Common Dizziness, somnolence, headache Common Ataxia, coordination abnormal, tremor, dysarthria, amnesia, memory impairment, disturbance in attention, paraesthesia, hypoaesthesia, sedation, balance disorder, lethargy Uncommon Syncope, stupor, myoclonus, loss of consciousness, psychomotor hyperactivity, dyskinesia, dizziness postural, intention tremor, nystagmus, cognitive disorder, mental impairment, speech disorder, hyporeflexia, hyperaesthesia, burning sensation, ageusia, malaise Rare Convulsions, parosmia, hypokinesia, dysgraphia, parkinsonism Eye disorders Common Vision blurred, diplopia Uncommon Peripheral vision loss, visual disturbance, eye swelling, visual field defect, visual acuity reduced, eye pain, asthenopia, photopsia, dry eye, lacrimation increased, eye irritation Rare Vision loss, keratitis, oscillopsia, altered visual depth perception, mydriasis, strabismus, visual brightness Ear and labyrinth disorders Common Vertigo Uncommon Hyperacusis Cardiac disorders Uncommon Tachycardia, atrioventricular block first degree, sinus bradycardia, congestive heart failure Rare QT prolongation, sinus tachycardia, sinus arrhythmia Vascular disorders Uncommon Hypotension, hypertension, hot flushes, flushing, peripheral coldness Respiratory, thoracic and mediastinal disorders Uncommon Dyspnoea, epistaxis, cough, nasal congestion, rhinitis, snoring, nasal dryness Rare Pulmonary oedema, throat tightness Not known Respiratory depression

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-09-24T15:36:00Z · SHA-256 82ee888afd9191364ca2885cfe33f3a6014857efdff1de95ea2361849731a42c · Passage 4bf3c300630d741556549c0a634cbc32491431f483c03d36ac28d1c609d4bef2 · Zeichen 1559–4837 im Abschnitt

Nebenwirkungen · Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

Pregabalin Viatris Pharma 25 mg hard capsules Pregabalin Viatris Pharma 50 mg hard capsules Pregabalin Viatris Pharma 75 mg hard capsules Pregabalin Viatris Pharma 100 mg hard capsules Pregabalin Viatris Pharma 150 mg hard capsules Pregabalin Viatris Pharma 200 mg hard capsules Pregabalin Viatris Pharma 225 mg hard capsules Pregabalin Viatris Pharma 300 mg hard capsules · Abschnitt 4.8 · PDF-Seite 10–11

HOS-132672 · Präparat HOS-097274

10 System Organ Class Adverse drug reactions Gastrointestinal disorders Common Vomiting, nausea, constipation, diarrhoea, flatulence, abdominal distension, dry mouth Uncommon Gastrooesophageal reflux disease, salivary hypersecretion, hypoaesthesia oral Rare Ascites, pancreatitis, swollen tongue, dysphagia Hepatobiliary disorders Uncommon Elevated liver enzymes* Rare Jaundice Very rare Hepatic failure, hepatitis Skin and subcutaneous tissue disorders Uncommon Rash papular, urticaria, hyperhidrosis, pruritus Rare Toxic epidermal necrolysis, Stevens-Johnson syndrome, cold sweat Musculoskeletal and connective tissue disorders Common Muscle cramp, arthralgia, back pain, pain in limb, cervical spasm Uncommon Joint swelling, myalgia, muscle twitching, neck pain, muscle stiffness Rare Rhabdomyolysis Renal and urinary disorders Uncommon Urinary incontinence, dysuria Rare Renal failure, oliguria, urinary retention Reproductive system and breast disorders Common Erectile dysfunction Uncommon Sexual dysfunction, ejaculation delayed, dysmenorrhoea, breast pain Rare Amenorrhoea, breast discharge, breast enlargement, gynaecomastia General disorders and administration site conditions Common Oedema peripheral, oedema, gait abnormal, fall, feeling drunk, feeling abnormal, fatigue Uncommon Generalised oedema, face oedema, chest tightness, pain, pyrexia, thirst, chills, asthenia Investigations Common Weight increased Uncommon Blood creatine phosphokinase increased, blood glucose increased, platelet count decreased, blood creatinine increased, blood potassium decreased, weight decreased Rare White blood cell count decreased * Alanine aminotransferase increased (ALT) and aspartate aminotransferase increased (AST).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-09-24T15:36:00Z · SHA-256 82ee888afd9191364ca2885cfe33f3a6014857efdff1de95ea2361849731a42c · Passage 3710e226b2665b8f89c41be31468c4a1462c16bab57e8f5d7c9f7866263108bc · Zeichen 4890–7381 im Abschnitt

Nebenwirkungen · Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

Pregabalin Viatris Pharma 25 mg hard capsules Pregabalin Viatris Pharma 50 mg hard capsules Pregabalin Viatris Pharma 75 mg hard capsules Pregabalin Viatris Pharma 100 mg hard capsules Pregabalin Viatris Pharma 150 mg hard capsules Pregabalin Viatris Pharma 200 mg hard capsules Pregabalin Viatris Pharma 225 mg hard capsules Pregabalin Viatris Pharma 300 mg hard capsules · Abschnitt 4.8 · PDF-Seite 11

HOS-132673 · Präparat HOS-097274

After discontinuation of short-term and long-term treatment with pregabalin withdrawal symptoms have been observed. The following symptoms have been reported: insomnia, headache, nausea, anxiety, diarrhoea, flu syndrome, convulsions, nervousness, depression, suicidal ideation, pain, hyperhidrosis and dizziness. These symptoms may indicate drug dependence. The patient should be informed about this at the start of the treatment. Concerning discontinuation of long-term treatment of pregabalin, data suggest that the incidence and severity of withdrawal symptoms may be dose-related (see sections 4.2 and 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-09-24T15:36:00Z · SHA-256 82ee888afd9191364ca2885cfe33f3a6014857efdff1de95ea2361849731a42c · Passage 64fe5e016f8aee7c06df7813d06a99bf9be54c620cf8da3008c7b1744678437f · Zeichen 7383–7994 im Abschnitt

Nebenwirkungen · Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

Pregabalin Viatris Pharma 25 mg hard capsules Pregabalin Viatris Pharma 50 mg hard capsules Pregabalin Viatris Pharma 75 mg hard capsules Pregabalin Viatris Pharma 100 mg hard capsules Pregabalin Viatris Pharma 150 mg hard capsules Pregabalin Viatris Pharma 200 mg hard capsules Pregabalin Viatris Pharma 225 mg hard capsules Pregabalin Viatris Pharma 300 mg hard capsules · Abschnitt 4.8 · PDF-Seite 11

HOS-132674 · Präparat HOS-097274

Paediatric population The pregabalin safety profile observed in five paediatric studies in patients with partial seizures with or without secondary generalisation (12-week efficacy and safety study in patients 4 to 16 years of age, n=295; 14-day efficacy and safety study in patients 1 month to younger than 4 years of age, n=175; pharmacokinetic and tolerability study, n=65; and two 1 year open label follow on safety studies, n=54 and n=431) was similar to that observed in the adult studies of patients with epilepsy. The most common adverse events observed in the 12-week study with pregabalin treatment were somnolence, pyrexia, upper respiratory tract infection, increased appetite, weight increased, and nasopharyngitis. The most common adverse events observed in the 14-day study with pregabalin

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-09-24T15:36:00Z · SHA-256 82ee888afd9191364ca2885cfe33f3a6014857efdff1de95ea2361849731a42c · Passage 8bd8c4a81000d81b0f53580932dbc5be7cd4b386b872043924f936ea097be33a · Zeichen 7996–8800 im Abschnitt

Nebenwirkungen · Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

Pregabalin Viatris Pharma 25 mg hard capsules Pregabalin Viatris Pharma 50 mg hard capsules Pregabalin Viatris Pharma 75 mg hard capsules Pregabalin Viatris Pharma 100 mg hard capsules Pregabalin Viatris Pharma 150 mg hard capsules Pregabalin Viatris Pharma 200 mg hard capsules Pregabalin Viatris Pharma 225 mg hard capsules Pregabalin Viatris Pharma 300 mg hard capsules · Abschnitt 4.8 · PDF-Seite 11–12

HOS-132675 · Präparat HOS-097274

11 treatment were somnolence, upper respiratory tract infection, and pyrexia (see sections 4.2, 5.1 and 5.2).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-09-24T15:36:00Z · SHA-256 82ee888afd9191364ca2885cfe33f3a6014857efdff1de95ea2361849731a42c · Passage e29274519b8e7198157d8caa5a0518e06c1897aa01531aad7e7d3a23f240d131 · Zeichen 8855–8965 im Abschnitt

Nebenwirkungen · Pregabalin Viatris Pharma (previously Pregabalin Pfizer)

Pregabalin Viatris Pharma 25 mg hard capsules Pregabalin Viatris Pharma 50 mg hard capsules Pregabalin Viatris Pharma 75 mg hard capsules Pregabalin Viatris Pharma 100 mg hard capsules Pregabalin Viatris Pharma 150 mg hard capsules Pregabalin Viatris Pharma 200 mg hard capsules Pregabalin Viatris Pharma 225 mg hard capsules Pregabalin Viatris Pharma 300 mg hard capsules · Abschnitt 4.8 · PDF-Seite 12

HOS-132676 · Präparat HOS-097274

Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-09-24T15:36:00Z · SHA-256 82ee888afd9191364ca2885cfe33f3a6014857efdff1de95ea2361849731a42c · Passage 42f7144177697b690f59b1bda795c3fd216297691cf296a2e1269a137feab3cd · Zeichen 8967–9322 im Abschnitt

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.